Zeaxanthin Dipalmitate Therapeutically Improves Hepatic Functions in an Alcoholic Fatty Liver Disease Model through Modulating MAPK Pathway by Xiao, J et al.
Title
Zeaxanthin Dipalmitate Therapeutically Improves Hepatic
Functions in an Alcoholic Fatty Liver Disease Model through
Modulating MAPK Pathway
Author(s) Xiao, J; Wang, J; Xing, F; Han, T; Jiao, R; Liong, EC; Fung, ML;So, KF; Tipoe, GL
Citation PLoS One, 2014, v. 9 n. 4, p. e95214
Issued Date 2014
URL http://hdl.handle.net/10722/196756
Rights Creative Commons: Attribution 3.0 Hong Kong License
Zeaxanthin Dipalmitate Therapeutically Improves
Hepatic Functions in an Alcoholic Fatty Liver Disease
Model through Modulating MAPK Pathway
Jia Xiao1,5,8., Jiteng Wang2., Feiyue Xing1, Tao Han2, Rui Jiao3, Emily C. Liong5, Man-Lung Fung6,7,
Kwok-Fai So4,5,7, George L. Tipoe5,7*
1Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, China, 2 School of Fishery, Zhejiang Ocean University,
Zhoushan, China, 3Department of Food Science and Engineering, Jinan University, Guangzhou, China, 4GMH Institute of Central Nervous System Regeneration, Jinan
University, Guangzhou, China, 5Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China, 6Department of
Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China, 7 Brain Hormone Healthy Aging Centre, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Hong Kong SAR, China, 8Department of Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, China
Abstract
In the current study, the therapeutic effects of zeaxanthin dipalmitate (ZD) on a rat alcoholic fatty liver disease (AFLD) model
were evaluated. After-treatment with ZD from the 5th week to the 10th week in a 10-week ethanol intragastric
administration in rats significantly alleviated the typical AFLD symptoms, including reduction in rat body weight,
accumulation of hepatic fat droplets, occurrence of oxidative stress, inflammation, chemoattractive responses and hepatic
apoptosis in the liver. The reduction of liver function abnormalities by ZD was partly through lower expression level of
cytochrome P450 2E1 (CYP2E1), diminished activity of nuclear factor kappa B (NF-kB) through the restoration of its inhibitor
kappa B alpha (IkBa), and the modulation of MAPK pathways including p38 MAPK, JNK and ERK. ZD treatment alone did not
pose obvious adverse effect on the healthy rat. In the cellular AFLD model, we also confirmed the inhibition of p38 MAPK
and ERK abolished the beneficial effects of ZD. These results provide a scientific rationale for the use of zeaxanthin and its
derivatives as new complementary agents for the prevention and treatment of alcoholic liver diseases.
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Introduction
The abuse of alcohol is a severe social problem in the world with
heavy burden in both health and economics. As one of the most
prevalent liver diseases caused by alcohol over-consumption,
alcoholic fatty liver disease (AFLD) affects over 2 million people in
the U.S. (U.S. Census Bureau, Population Estimates, 2004). In
China, it is estimated that 2.8% of population has AFLD or
suspected AFLD [1]. The prevalence of AFLD is influenced by
many factors, not only the abuse of alcohol, but also the gender
discrepancy, genetic defects and other environmental factors, since
only 1 in 5 heavy drinkers develops alcoholic hepatitis [2]. In the
past decade, significant progress has been achieved to understand
the molecular and cellular pathological mechanisms contributing
to AFLD. The spectrum of AFLD ranges from simple steatosis (fat
accumulation without inflammatory infiltration) to alcoholic
steatohepatitis (ASH), hepatic fibrosis and cirrhosis [3]. ASH is
characterized by the presence of inflammatory foci within the liver
and the occurrence of macrophage activation and chemoattraction
[4]. These mechanisms are closely associated with the production
of reactive oxygen species (ROS) induced by ethanol and its
metabolites, as well as the activation of innate immunity (e.g. the
production of pro-inflammatory cytokines and chemokines) [5].
Therefore, administration of therapy directed against the initiation
and progression of AFLD should at least target one or several key
pathological events related to AFLD, such as steatosis, hepatic
oxidative stress, and inflammation.
Zeaxanthin and luteins are the common carotenoid alcohols
found in nature. As a potent free-radical scavenger as well as its
hepatotropic and lipotropic distribution, zeaxanthin is considered
as a promising hepato-protective agent against several liver
diseases, including acute liver injury [6], liver cancer [7], and
non-alcoholic fatty liver disease (NAFLD) [8,9]. It is found that in
the liver, supplementary intake of zeaxanthin could prevent
hepatic oxidative stress and halt inflammation/fibrosis during the
development of NAFLD, then reduces the chance of progressing
to end-stage liver disease[8]. However, there is very limited
information regarding the role and mechanism of zeaxanthin in
AFLD. In addition, zeaxanthin is an important component of
several natural antioxidant mixtures, such as in wolfberry, which is
newly identified hepato-protective agent [10,11]. Investigating the
protective mechanism of ZD against AFLD may shed new
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direction on the pharmacological study of this compound.
Considering the similarity of the pathological mechanisms
between AFLD and NAFLD, the present study aimed to
investigate the possible ameliorative and therapeutic effects of
zeaxanthin (zeaxanthin dipalmitate) on ethanol induced fatty liver
disease rat model.
Materials and Methods
Reagents and antibodies
Zeaxanthin dipalmitate (ZD) was purchased from Wako Pure
Chemical Industries Ltd (Osaka, Japan). The structure of
zeaxanthin is shown in Figure 1. Antibodies for cytochrome
P450 2E1 (CYP2E1) and inhibitor of kappa B alpha (IkBa) were
bought from Millipore (Billerica, MA) and Cell Signaling
(Danvers, MA), respectively. Mitogen-activated protein kinase
(MAPK) antibodies, including total p38 MAPK, phosphorylated
p38 MAPK at Thr180/Tyr182, total c-Jun N-terminal kinase
(JNK), phosphorylated JNK at Thr183/Tyr185, total extracellular
signal-regulated kinase (ERK) and phosphorylated ERK at
Tyr204 were purchased from Cell Signaling. Hoechset 33342,
propidium iodide, SB203580 (p38 inhibitor), SP600125 (JNK
inhibitor) and PD98059 (ERK inhibitor) were bought from Sigma-
Aldrich (St. Louis, MO). RPMI-1640 cell culture medium, FBS
and other cell culture consumables were obtained from Gibco (Life
Technologies, Calsbad, CA).
Animals and treatments
Twenty-four female Sprague-Dawley (SD) rats weighing from
180–200 g were obtained from the animal center of Zhejiang
Experimental Animal Center. All experimental procedures were
approved by the ethical committee of Zhejiang Ocean University.
Before experiment, rats were adapted to the environment for one
week with free access to regular chow and water. After that, rats
were randomly and equally assigned to 4 groups (n = 6 per group)
namely: (1) control group was fed with regular chow and water for
10 weeks. During this period, rats were orally fed with 5% Tween
80 in PBS which was the solvent used for ZD from the 5th week to
the 10th week; (2) AFLD group was intragastrically fed with 4.0 g/
kg ethanol diluted in distilled water in addition to oral regular
chow and water for 10 weeks; (3) vehicle-ZD group was fed with
regular chow and water for 10 weeks. During the period, rats were
orally fed with 25 mg/kg body weight ZD (in 5% Tween 80-PBS)
every day from the 5th week to the 10th week; and (4) AFLD+ZD
group which received similar treatment as the AFLD group for the
first five weeks and then orally fed with 25 mg/kg body weight ZD
and intragastric administration of ethanol from the 5th week to the
10th week. Animal body weight was measured weekly to determine
the effects of ethanol and ZD on body weight and to adjust the
intragsatric ingestion of ethanol. Pilot study showed that oral
feeding and intragastric administration of tween/PBS showed no
obvious influence on the hepatic histology of rats (data not shown).
Previous study showed that 25 mg/kg ZD could reduce hepatic
fibrosis in rats at which we based the dose of ZD [12]. After 8 hrs
of the last administration of ethanol and ZD, rats were euthanized
with anoverdose of pentobarbitone. At week 10, blood samples
were collected 1 hour after the ethanol administration in order to
measure the blood alcohol level. Serum samples were obtained
from whole blood by centrifugation at 3,000 rpm for 15 min.
Liver samples were collected for histological examination,
molecular and biochemical analyses.
Liver tissue processing
Liver tissue samples were fixed in 10% phosphate-buffered
formalin, and then embedded in paraffin blocks. Five-micrometer
tissue sections were cut and stained with hematoxylin and eosin
(H&E) for histological analysis under light microscope (Nikon,
Japan). The mean area of necrosis was determined by dividing the
Figure 1. Structure of zeaxanthin.
doi:10.1371/journal.pone.0095214.g001
Table 1. Primer sequences for Real-time PCR.
Target gene Direction Primer sequence (59-39)
CAT Sense GAGGCAGTGTACTGCAAGTTCC
Anti-sense GGGACAGTTCACAGGTATCTGC
SOD1 Sense GCAGGGCGTCATTCACTT
Anti-sense AGACTCAGACCACATAGGGA
Bcl-2 Sense TGGGATACTGGAGATGAAGACT
Anti-sense CGACGGTAGCGACGAGA
Bax1 Sense GGTTGCCCTCTTCTACTTTG
Anti-sense CAGCCACCCTGGTCTTG
CYP2E1 Sense CCTTTCCCTCTTCCCATCC
Anti-sense AACCTCCGCACATCCTTCC
b-actin Sense GAGACCTTCAACACCCCAGCC
Anti-sense TCGGGGCATCGGAACCGCTCA
CAT, catalase; CYP2E1; cytochrome P450 2E1; SOD1; superoxide dismutase 1.
doi:10.1371/journal.pone.0095214.t001
Table 2. The effect of ethanol consumption and ZD
treatment on rat body weights.
Group Body weights (g)
Week 1 Week 4 Week 10
Control 189.265.6a 223.9610.7a 301.4619.3a
AFLD 191.667.1a 217.6611.8a 259.5615.1b
Vehicle-ZD 190.566.0a 220.3611.0a 298.6621.2a
AFLD+ZD 186.965.7a 226.969.9a 277.5614.2c
Values are means 6 S.D.; n = 6.
Different letters (e.g. a and b) indicate significant change (at least p,0.05).
AFLD, alcoholic fatty liver disease; ZD, zeaxanthin dipalmitate.
doi:10.1371/journal.pone.0095214.t002
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Figure 2. Ameliorative effects of zeaxanthin dipalmitate (ZD) on ethanol-induced hepatic steatosis and inflammation. (A)
Representative histological changes of control group; alcoholic fatty liver disease (AFLD) group; vehicle-ZD group; and AFLD+ZD group after 10-week
4 g/kg ethanol administration with or without daily 25 mg/kg ZD administration from the 5th week to the 10th week. Tissue sections were stained
with H&E (200x magnification). Yellow arrows indicate fat accumulation in the liver while blue arrow indicates typical inflammatory infiltration (Bar: 20
microns) (B) Liver necrotic area from each group. (C) Hepatic triglyceride (TG) content from each group. Different letters (e.g. a and b) indicate
significant differences between groups (at least p,0.05). Data presented are expressed as Mean 6 S.D. (n = 6).
doi:10.1371/journal.pone.0095214.g002
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sum areas of necrotic regions by the total number of fields per
group [13].
Serum biochemical assays
The serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels of rats were detected using the
corresponding detection kits provided by Liaoning Taike Medical
Science Company, Liaoning, China and according to the
manufacture’s protocols. Serum triglyceride (TG) and total
cholesterol (TC) levels as well as liver tissue TG content were
measured by commercial kits from Cayman Chemical (Cayman
Chemical, Ann Arbor, MI). Serum ethanol level was measured
with an alcohol dehydrogenase kit (Sigma), according to the
protocol supplied by the manufacturer.
Terminal deoxynucleotidyl transferase-mediated dUTP-
nick end labeling (TUNEL) assay
To demonstrate the apoptosis in the liver, the TUNEL assay
which detects 39 hydroxyl ends in fragmented DNA as an early
event in apoptotic cascade was used. After dewaxing and
rehydration of the paraffin-embedded liver tissue sections, staining
was performed using a TUNEL assay with the in situ cell death
detection kit (Roche, Basel, Switzerland). The intensity of positive
immunostaining of Fast Red of TUNEL was examined by light
microscope (Olympus, Tokyo, Japan) and quantified by ImageJ
software.
Measurement of oxidative stress and lipid peroxidation in
the liver
Liver tissue was homogenized in Tris-HCl buffer (20 mM,
pH 7.4) and then centrifuged at 25006g at 4uC for 10 min. Two
hundred microliters of supernatant was analyzed for malondialde-
hyde (MDA) levels using a kit (Bioxytech MDA-586; Oxis
Research, Foster City, CA) and the value was read at 586 nm.
For the measurement of serum 8-isoprostane level, serum samples
were quantified using the 8-isoprostane EIA kit (Cayman
Chemical) according to manufacturer’s instructions.
Hepatic alcohol dehydrogenase (ADH) activity
Since ADH is one of the key enzymes responsible for the
metabolism of ethanol in the liver, we measured its activity in
different groups by using commercial kit (JianCheng Bioengineer-
ing Institute, Nanjing, China) according to the manufacturer’s
instructions.
Cell culture and treatments
The BRL-3A cell line was supplied by the Cell Bank of Type
Culture Collection of Chinese Academy of Sciences (Shanghai,
China). It was cultured in RPMI-1640 with 10% (v/v) FBS at
37uC with 5% CO2 using a cell incubator. When cells reached a
confluence of 60–70%, they were divided into 9 groups (n = 5)
including: (1) control group (treated with 5% Tween 80 in PBS
which was the solvent for ZD); (2) ethanol group (treated with
200 mM ethanol); (3) ethanol + ZD group (treated with 200 mM
ethanol and 1 mM ZD); (4–6) inhibitor only groups [treated with
p38 MAPK inhibitor – SB203580 (15 mM), JNK inhibitor –
SP600125 (15 mM), and ERK inhibitor – PD98059 (15 mM),
respectively]; (7–9) ethanol, ZD and MAPK inhibitor co-treatment
groups (treated with 200 mM ethanol, 1 mM ZD, and corre-
sponding MAPK inhibitors). The treatment duration was 24 hrs.
Inhibitors for MAPK were added 2 hrs before the ethanol
treatment and the specificity of each inhibitor was confirmed in
a pilot study (data not shown). ZD was added 1 hr before the
ethanol treatment. The dose selection of ZD was based on a
previous study on carbon tetrachloride-induced rat hepatocyte
injury model [14].
MTT assay
Cell viability was evaluated by the conversion of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
Sigma-Aldrich) to a purple color product by cellular mitochondria.
After drug treatment, cells from each group were washed by sterile
PBS three times and then incubated with 5 mg/ml MTT for
3 hrs, and subsequently dissolved in dimethyl sulfoxide (DMSO).
The absorbance of MTT was measured at 570 nm.
Activities of caspase-3/7
Activities of caspases-3 and -7 from both liver tissue lysates and
cell lysates were measured using Caspase-Glo 3/7 Assay Systems
(Promega, Madison, WI) according to the user manual. The
luminescence was read in a Glomax luminometer (Promega) and
expressed as fold change in caspase 3/7 activity from control.
RNA extraction and quantitative real-time PCR
Total RNA of each rat was extracted from the liver sample
using RNeasy Mini Kit (Qiagen, Valencia, CA) and then
quantified with the spectrophotometer (Beckman Coulter, Full-
erton, CA). The reverse-transcription of total RNA was performed
by SuperScriptTM First-Strand Synthesis System (Life Technolo-
gies). The mRNA expression levels of catalase (CAT), superoxide
dismutase 1 (SOD1), CYP2E1, Bcl-2, and Bax1 were measured by
Perfect Real-time system on Applied Biosystems 7300 Real-time
PCR system in triplicates. Parallel amplification of b-actin was
used as the internal control. The reaction condition of all
amplifications was: 10 min at 95uC, and 40 cycles of 15 sec at
95uC, 30 sec at 60uC, and 30 sec at 72uC. Primer sequences of
target and house-keeping genes were listed in Table 1. Fold
change of each gene was calculated by using the comparative Ct
method. All quantitative PCR procedures, including the design of
primers, validation of PCR environment, and quantification
methods were performed according the MIQE guideline [15].
Protein extraction and Western blotting
Liver samples were homogenized in lysis buffer (150 mM NaCl,
10 mM HEPES, pH 7.9, 1 mM EDTA, 0.6% NP-40, 0.5 mM
PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotonin, and 10 mg/ml
trypsin inhibitor). Samples were then sonicated and incubated on
ice for 30 minutes. Debris was removed by centrifugation at
Table 3. The effects of ethanol consumption and ZD
treatment on rat serum markers.
Group ALT (IU/L) AST (IU/L) TG (mmol) TC (mmol)
Control 43.765.0a 133.2613.5a 0.460.1a 1.160.2a
AFLD 65.266.6b 141.7615.5a 0.760.1b 1.760.3b
Vehicle-ZD 44.565.2a 140.1616.9a 0.460.2a 1.060.2a
AFLD+ZD 41.864.9a 138.6617.2a 0.560.1a 1.260.2a
Values are means 6 S.D.; n = 6.
Different letters (e.g. a and b) indicate significant change (at least p,0.05).
AFLD, alcoholic fatty liver disease; ZD, zeaxanthin dipalmitate; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; TG, triglyceride; TC, total
cholesterol.
doi:10.1371/journal.pone.0095214.t003
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10,000 rpm. Cellular total protein was extracted using a M-PER
Mammalian Protein Extraction Reagent (Pierce, Rockford, IL)
Protein concentrations of each sample were determined in order to
calculate the loading amount. Samples were separated in a
denaturing 10% polyacrylimide gel and transferred to a 0.1 mm
pore nitrocellulose membrane. Non-specific binding sites were
blocked with Tris-buffered saline (TBS; 40 mM Tris, pH 7.6,
300 mM NaCl) containing 5% nonfat dry milk (Cell Signaling) for
1 hour at room temperature. Membranes were then incubated
with appropriate primary antibodies in TBS with 0.1% Tween 20
(TBST). Membranes were washed and incubated with secondary
antibodies conjugated to horseradish peroxidase to show the bands
with ECL buffer (GE Healthcare, UK). Parallel blotting of b-actin
(Cell Signaling) was used as internal control.
Enzyme-linked immunosorbent assay (ELISA) of cytokines
and chemokines
ELISA measurements of TNF-a, IL-1b, IL-6, and MCP-1
protein expression levels were performed using kits from
PeproTech (PeproTech Inc., Rocky Hill, NJ). Detailed procedures
were performed according to the protocols provided by the
manufacturer.
NF-kB activity
The activation of transcriptional factor NF-kB was measured by
using a NF-kB p65 transcription factor assay kit from Pierce,
according to manufacturer’s instructions. Nuclear protein from the
liver tissue was extracted using a commercial kit from Pierce.
Statistical analysis
All values were expressed as means and standard deviations.
Statistical comparisons between groups were done using a
variance (ANOVA) and followed by post hoc LSD tests. A
p,0.05 was considered to be statistically significant (SPSS version
17.0., IBM Corporation, Armonk, New York).
Results
ZD treatment did not change blood alcohol level but
increased rat body weight which was influenced by
ethanol consumption
At week 10, blood alcohol levels 1 hour after ethanol
administration were similar in the ZD-treated group
(266.3662.2 mg/100 ml) and the control group (294.46
69.1 mg/100 ml), indicating that supplementation with ZD did
not alter the ethanol metabolism and any observed effects from
ZD were not likely due to its effects on ethanol absorption. Before
the start and 4 weeks after the experiment, there was no significant
difference in rat body weights between each group. After 10-week
4.0 g/kg ethanol administration, rats from the AFLD group
showed significantly decreased in body weight when compared
with the control group (p,0.05). However, when ZD was co-
treated from the 5th week to the 10th week, rats from the ALD+ZD
group increased in body weight when compared with the AFLD
group (p,0.05). Notably, vehicle-ZD treatment did not signifi-
cantly alter the body weight of healthy rats (Table 2).
ZD treatment improved liver histology
When compared with the control group, the liver of ethanol-
administered rats exhibited evidence of AFLD phenotypes,
including fat droplet deposition and accumulation of inflammatory
cells around the centrolobular vein (Figure 2A). Co-treatment with
ZD significantly improved the hepatic pathology comparable to
the control phenotype, with reduced number of lipid droplet and
inflammatory foci (Figure 2A). The mean liver necrosis and
hepatic TG content results further validated these findings
(Figures 2B and 2C). Vehicle-ZD administration did not influence
the liver morphology of the healthy rats. In line with the
histolopathological results, ethanol treatment significantly in-
creased the serum ALT level. ZD administration reduced it to
the control level. AST level was not influenced by both ethanol
and ZD treatments (Table 3). In addition, ZD treatment
significantly inhibited ethanol-induced increase in serum TG
and TC levels, which was consistent with the result of fat
accumulation in the liver (Table 3 and Figure 2A).
ZD treatment attenuated hepatic oxidative stress
Oxidative stress is one of the most prominent pathological
events during the progression of AFLD since it links lipid
metabolism dysfunction and the occurrence of downstream
inflammation and apoptosis [16]. To study the possible anti-
oxidative stress effects of ZD, the mRNA expression of hepatic
endogenous CAT and SOD1 was firstly evaluated. Chronic
consumption of ethanol significantly reduced the mRNA expres-
sion level of both CAT and SOD1, indicating an impaired
antioxidant status of the liver cells (Figures 3A and 3B).
Administration of ZD recovered their expression levels compara-
ble to the controls and without affecting the healthy rats
(Figures 3A and 3B). CYP2E1 is one of the major mediators of
oxidative stress during ethanol metabolism [17]. We also found
that in our AFLD model, the mRNA and protein expression of
CYP2E1 was markedly up-regulated by the ethanol administra-
tion, but it was significantly reduced by the after-treatment of ZD.
Very interestingly, vehicle-ZD treatment down-regulated the basal
mRNA and protein level of CYP2E1 (Figure 3C and 3D). In
addition, in terms of end-products of oxidative stress, we measured
the level of serum MDA and plasma 8-isoprostane in each group.
Induction of AFLD significantly increased the formation level of
Figure 3. Zeaxanthin dipalmitate (ZD) attenuated hepatic oxidative stress and alcohol metabolizing enzyme induced by ethanol.
Hepatic expression of (A) catalase (CAT) mRNA, (B) superoxide dismutase 1 (SOD-1) mRNA, (C) cytochrome P450 2E1 (CYP2E1) mRNA, (D) CYP2E1
protein, and (E) activity of alcohol dehydrogenase (ADH) after 10-week 4g/kg ethanol administration with or without daily 25 mg/kg ZD
administration from the 5th week to the 10th week. Different letters (e.g. a and b) indicate significant differences between groups (at least p,0.05).
Data presented are expressed as Mean 6 S.D. (n = 6).
doi:10.1371/journal.pone.0095214.g003
Table 4. The effects of ethanol consumption and ZD
treatment on rat serum MDA and plasma 8-isoprostane levels.
Group MDA (nmol/L) 8-isoprostane (pg/ml)
Control 7.561.2a 103.8612.2a
AFLD 17.962.5b 255.6629.4b
Vehicle-ZD 7.261.1a 97.4611.0a
AFLD+ZD 11.362.1c 139.6618.3c
Values are means 6 S.D.; n = 6.
Different letters (e.g. a and b) indicate significant change (at least p,0.05).
AFLD, alcoholic fatty liver disease; ZD, zeaxanthin dipalmitate; MDA,
malondialdehyde.
doi:10.1371/journal.pone.0095214.t004
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PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e95214
MDA and 8-isoprostane, which was consistent with the results of
CAT/SOD1 and CYP2E1. Intake of ZD significantly reduced
these formations of the oxidative stress products (Table 4). In line
with the oxidative stress markers, the activity of hepatic ADH was
also induced by ethanol but it was suppressed by the after-
treatment with ZD, which was also comparable to the control level
(Figure 3E).
Administration of ZD alleviated hepatic inflammation
and apoptosis through MAPK pathway
To further investigate the beneficial effects of the therapeutic
treatment ZD on AFLD, we then measured the change of protein
expression of key markers of inflammation (TNF-a, IL-1b and IL-
6) and chemoattraction (MCP-1) in each experimental group.
Ten-week consumption of ethanol significantly up-regulated the
expression levels of these proteins in the AFLD rat liver.
Therapeutic treatment with ZD reduced or even abolished the
influence of ethanol on these pro-inflammatory mediators
(Figures 4A–4D).
To investigate the underlying mechanisms of ZD-mediated
hepatic improvements, we measured the expressional changes of
key MAPK members in rats since they were heavily involved in
the fatty liver diseases [10,18]. Administration of ethanol
significantly increased the phosphorylation of both p38 MAPK
and JNK, but decreased the phosphorylation of ERK (Figure 5C).
After-treatment with ZD abolished the influence of ethanol on
phosphorylated p38 MAPK and JNK, but not the phosphorylation
form of ERK. Both treatments of ethanol and ZD did not
demonstrate any effects on the total form expression of p38
MAPK, JNK and ERK (Figure 5C).
The intensity of Fast Red staining was pronounced in the AFLD
rats but it was significantly reduced after the ZD treatment
(Figures 6A and 6B). This observation was validated by the down-
regulation of Bax1 mRNA level and the up-regulation of Bcl-2
mRNA level after the ZD treatment. The ALFD treated rats
showed increased in Bax1 and decreased in Bcl-2 mRNA levels
(Figures 6D and 6E). The activity of caspase 3/7 also exhibited
similar trend to Bax1 (Figure 6C)
Figure 4. Zeaxanthin dipalmitate (ZD) attenuated hepatic inflammation induced by ethanol. Hepatic protein expression of (A) tumor
necrosis factor alpha (TNF-a), (B) interleukin (IL)-1b, (C) IL-6, and (D) monocyte chemotactic protein (MCP)-1 after 10-week 4 g/kg ethanol
administration with or without daily 25 mg/kg ZD administration from the 5th week to the 10th week. Different letters (e.g. a and b) indicate
significant differences between groups (at least p,0.05). Data presented are expressed as Mean 6 S.D. (n = 6).
doi:10.1371/journal.pone.0095214.g004
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Figure 5. Zeaxanthin dipalmitate (ZD) played hepato-protective effects through modulating transcription factor and MAPK
pathways. Hepatic expression of (A) cytosolic inhibitor of kappa B alpha (IkBa) protein, (B) nuclear factor kappa B (NF-kB) activity and (C) MAPK
pathway members after 10-week 4 g/kg ethanol administration with or without daily 25 mg/kg ZD administration from the 5th week to the 10th
week. Different letters (e.g. a and b) indicate significant differences between groups (at least p,0.05). Data presented are expressed as Mean 6 S.D.
(n = 6).
doi:10.1371/journal.pone.0095214.g005
Zeaxanthin Dipalmitate Improves AFLD
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In vitro investigation of the involvement of MAPK
pathways
To further confirm whether the MAPK signaling pathways
mediated the hepato-protective functions of ZD, rat hepatocyte
cell line BRL-3A was pre-incubated with SB203580 (inhibitor of
p38, 15 mmol/L), SP600125 (inhibitor of JNK, 15 mmol/L) or
PD98059 (inhibitor of ERK, 15 mmol/L) before ethanol treatment
and ZD intervention. Inhibitor single treatment did not affect the
cell viability but PD98059 slightly induced expression of TNF-a,
cellular apoptotic ratio and the activity of caspase-3/7 (Table 5)
[19]. When MAPK inhibitors were pre-treated prior to the 24-h
ethanol exposure, SB203580 and PD98059 did not significantly
influence the effects of ethanol on cell viability, inflammatory and
apoptotic responses. However, inhibition of JNK by SP600125
attenuated cellular apoptosis induced by ethanol (Table 5). Co-
treatment with ZD partially reversed the effects of ethanol on cell
viability, TNF-a expression, apoptotic ratio and caspase-3/7
activity. Such effects were abolished by the addition of inhibitors of
p38 MAPK and ERK, but not JNK inhibitor (Table 5).
Next, we examined the effects of ethanol exposure and ZD co-
treatment on the expression of phosphorylated and total forms of
MAPK family members. It was shown that 24-h ethanol exposure
did not change both the phosphorylated and the total forms of p38
MAPK and ERK, but it significantly promoted the phosphory-
lation of JNK. Such elevation was abolished by the addition of ZD
(Figure 7). Co-treatment with ZD did not affect the phosphory-
lated and total forms of p38 MAPK but it slightly decreased the
level of ERK (phosphorylated and total forms) (Figure 7).
Discussion
AFLD is one of the biggest burdens to society, particularly in
affluent regions. So the development of clinical therapy of AFLD
has received much attention since abstinence is currently the only
effective means to control the AFLD progression [20]. In recent
years, emerging evidence suggests that several kinds of herbal
derivatives may play protective and therapeutic roles against
AFLD, such as wolfberry [21], resveratrol [22], green tea [23], and
Figure 6. Zeaxanthin dipalmitate (ZD) attenuated hepatic apoptosis induced by ethanol administration. (A) Representative hepatic
apoptotic changes of control group; alcoholic fatty liver disease (AFLD) group; vehicle-ZD group; and AFLD+ZD group after 10-week 4 g/kg ethanol
administration with or without daily 25 mg/kg ZD administration from the 5th week to the 10th week. Tissue sections were stained with TUNEL assay
kit (200x magnification; Bar: 20 microns). The results are further confirmed by the quantification of the Fast Red staining (B) and expression of
caspase-3/7 activity (C) Bcl-2 mRNA (D) and Bax1 mRNA (E). Different letters (e.g. a and b) indicate significant differences between groups (at least
p,0.05). Data presented are expressed as Mean 6 S.D. (n = 6).
doi:10.1371/journal.pone.0095214.g006
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silibinin [24]. Due to their wide availability and low side-effect
when administered within a reasonable dose range, the application
of alternative herbal medicine is quite promising. However, for
some herbal compounds like wolfberry, which consist of several
monomers, although they possess potent hepato-protective prop-
erties, the identification of their active monomer(s) is still on the
way [10]. In the current study, we demonstrated that 10-week
administration of ethanol in rat caused typical AFLD features,
including reduction of body weight, steatosis, hepatic oxidative
stress, inflammation, chemoattraction and apoptosis. After treat-
ment with zeaxanthine (ZD), from the 5th week to the 10th week of
the experiment, it exhibited potent hepatoprotective, anti-oxida-
tive stress, anti-inflammatory and anti-apoptotic properties. Such
effects were achieved partially through the modulatory activity of
transcription factor NF-kB and MAPK pathways including p38
MAPK and ERK, but not JNK. These results also demonstrated
that ZD may partially account for the hepato-protective role of
wolfberry and other herbal mixtures.
Serum ALT and AST are clinical biochemical markers for
general hepatic cellular injury. Under healthy condition, they are
contained within the hepatocytes. When there is a hepatic
damage, either endogenous or exogenous, these enzymes will be
released from hepatocytes into the circulation [25]. In our AFLD
model, consumption of ethanol significantly increased the serum
level of ALT but not AST, indicating the occurrence of hepatic
injury, which was consistent with the histological results.
Addition of ZD not only reduced ALT content to the control
level, but also significantly ameliorated the histopathological
changes (e.g. number of fat deposition and inflammatory foci)
(Figure 1 and Table 3). Also, the attenuation of steatosis in the liver
by ZD was consistent with the reduction of the serum and hepatic
TG and TC content. In addition, the reduction of inflammatory
foci in the ZD-AFLD rat liver section was consistent with the
down-regulation of expression level of hepatic pro-inflammatory
markers and chemokines (Figure 3). It is now well recognized that
inflammation is the key event which drives the transition from
simple steatosis to hepatitis, both in AFLD and NAFLD [26]. The
release of pro-inflammatory cytokines and chemokines are
primarily from the hepatic resident macrophage–Kupffer cells
[27]. Effective control of hepatic inflammation, either directly by
inhibiting the activation of Kupffer cells or indirectly by
suppressing transcription factor (e.g. NF-kB) may provide impor-
tant beneficial effect on the progression and severity of AFLD. We
also found that the activation of NF-kB by ethanol administration
was significantly counteracted by ZD treatment, through the
recovery of its cytosolic inhibitor IkBa, further ameliorating of the
severity of ethanol-induced liver injury (Figures 4A and 4B).
The antioxidant properties of ZD had been shown in this study.
Generation of hepatic oxidative stress from ROS and RNS is the
direct consequence of ethanol metabolism. Since (1) CYP2E1 can
produce ROS during its catalytic circle and (2) the activity of
Table 5. The effects of ethanol, ZD, and MAPK inhibitors on rat hepatocyte BRL-3A viability, inflammatory and apoptotic marker
levels.
Group Viability (%control) TNF-a (%control) Percentage of apoptosis (%) Caspase-3/7 (%control)
Control 100.069.3a 100.0612.2a 3.460.5a 100.0610.8a
Ethanol 62.567.1b 309.5636.8b 37.465.2b 307.7637.6b
Ethanol+ZD 77.868.0c 221.8623.2c 19.962.4c 236.2622.1c
ip38 89.768.9a 122.3615.4a 5.161.1a 109.3611.5a
iJNK 92.769.6a 112.0610.7a 5.560.6a 98.968.8a
iERK 98.468.9a 140.5617.0d 10.861.5d 144.3615.0d
Ethanol+ip38 63.366.2b 283.6630.4b 33.662.9b 268.0633.9b
Ethanol+iJNK 70.766.0b,c 272.2628.8b 30.163.4f 229.7624.4c
Ethanol+iERK 61.164.5b 319.8634.7b 35.965.0b 315.5635.0b
Ethanol+ZD+ip38 60.166.9b 288.4631.1b 35.766.6b 313.0634.7b
Ethanol+ZD+iJNK 79.366.6c 196.9622.2c 15.363.0e 208.3621.9c
Ethanol+ZD+iERK 58.367.3b 275.8635.0b 30.963.0b 288.4636.6b
Values are means 6 S.D., n = 5; Results of TNF-a, percentage of apoptosis, and caspase-3/7 are against corresponding cell viability.
Different letters (e.g. a and b) indicate significant change (at least p,0.05).
ZD, zeaxanthin dipalmitate; TNF-a, tumor necrosis factor alpha; ip38, inhibitor of p38 MAPK (SB203580); iJNK, inhibitor of JNK (SP600125); iERK, inhibitor of ERK
(PD98059).
doi:10.1371/journal.pone.0095214.t005
Figure 7. Effects of ethanol and zeaxanthin dipalmitate (ZD) on
MAPK pathways in BRL-3A cells. Cellular changes of MAPK pathway
members after 24-h 200 mM ethanol exposure with or without 1 mM ZD
pre-treatment.
doi:10.1371/journal.pone.0095214.g007
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CYP2E1 can be elevated by chronic treatment with ethanol,
CYP2E1 is considered as a major contributor to ethanol-induced
hepatic oxidative stress [16,17]. In this study, both mRNA and
protein expression of CYP2E1 was induced by a 10-week
administration of ethanol, leading to the increase of oxidative
products (MDA and 8-isoprostane) and the decrease of endoge-
nous antioxidant enzyme levels (CAT and SOD1). This result was
in parallel with a previous study showing that CYP2E1 inhibitor
chlormethiazole could partially protect the rat liver from ethanol-
induced injury by inhibiting CYP2E1 activity in vivo [28]. Co-
treatment with ZD effectively counteracted the induction of
oxidative stress and restored the antioxidant defense of the cell,
indicating its potent hepatic antioxidant property during AFLD
development (Figure 2 and Table 4). The occurrence of oxidative
stress and inflammation forms a positive pathogenic feedback loop.
Therefore, the beneficial effects of ZD on both oxidative stress and
inflammation strongly suggested its potential usage in therapy and
prevention of hepatic injury.
Apoptosis is one of the most recognized features of AFLD [29].
In the current study, we confirmed that the number of apoptotic
cells after ethanol treatment was significantly increased, both in vivo
and in vitro. The induction of apoptosis was associated with the
increase of caspase activity and the decrease of anti-apoptotic
molecule (e.g. Bcl-2) (Figure 5). ZD treatment evidently reduced
the apoptotic ratio through restoring Bcl-2 expression and
reducing caspase activity. These data supported the beneficial
effects of ZD on the liver by improving the anti-apoptotic
response, which was consistent with a recent study showing the
anti-apoptotic function of zeaxanthin through Bcl-2 and MAPK in
human dermal papilla cells [30].
The core purpose of the current study was to investigate the
potential molecular signaling pathways that were involved in the
hepato-protective functions of ZD. We speculated the role of
MAPK pathways in ZD hepato-protective effects since the
polysaccharides portion of wolfberry potently alleviated NAFLD
by modulating the MAPK pathways [10] and ZD was also one of
the components of wolfberry [31]., We found that chronic ethanol
treatment induced the activity (phosphorylated form) of p38
MAPK and JNK but decreased ERK. These results were
consistent with previous findings from our wolfberry study [10].
Addition of ZD abolished the induction of p38 MAPK and JNK
but not ERK. Notably, in the cell model, since (1) inhibitor of p38
MAPK or ERK alone did not ameliorate ethanol-induced cellular
injury but effectively abolished the beneficial influence of ZD on
the hepatic functions, and (2) ethanol or ZD incubation did not
significantly regulate the phosphorylation and basal protein
expression of p38 MAPK and ERK, it was reasonable to conclude
that both p38 MAPK and ERK were closely associated with the
ZD ameliorative functions against ethanol exposure-induced
hepatocytes dysfunctions (Table 5 and Figure 7). Interestingly,
JNK seemed to play a different role in ethanol-induced liver
injury, because (1) ethanol exposure significantly elevated the
phosphorylated level of JNK in BRL-3A cells and ZD co-
treatment restored its basal level, (2) JNK inhibitor alone
attenuated apoptosis, and (3) inhibition of JNK did not affect the
alleviative effects of ZD. However, JNK was partially responsible
for ethanol-induced cellular apoptosis but not involved in the
protection from ZD co-treatment (Table 5 and Figure 7). This
result is consistent with a previous report that p38 MAPK and
ERK, but not JNK, are involved in the amelioration of carbon
monoxide against ethanol-induced oxidative damage and inflam-
matory stress [32]. There is limited information about the
signaling pathways regulated by zeaxanthin. Our study may
provide impetus for further exploration of beneficial effects of
zeaxanthin in the humans, not only confined in the liver.
In summary, we conclude that ZD therapeutically reduced
ethanol-induced hepatotoxicity by (1) improving hepatic histology,
(2) ameliorating steatosis, (3) increasing endogenous antioxidant
enzyme level through CYP2E1-dependent pathway, (4) demising
pro-inflammatory response and chemoattraction, and (5) attenu-
ating hepatic apoptosis. These beneficial effects were partially
regulated via the reduction of NF-kB activity and the modulation
of p38 MAPK and ERK pathways. We suggest that ZD could be a
good alternative herbal medicine that has great therapeutic and
hepatoprotective properties for the treatment of liver diseases.
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